IMEIK(SZ:300896) Xin Lang Cai Jing·2026-02-05 02:18Core Viewpoint - Aimeike's stock price has increased by 5.09% on February 5, reaching 155.87 CNY per share, with a total market capitalization of 47.165 billion CNY, marking a cumulative increase of 6.15% over three consecutive days [1] Group 1: Company Overview - Aimeike Technology Development Co., Ltd. is located in Chaoyang District, Beijing, and was established on June 9, 2004, with its IPO on September 28, 2020 [1] - The company's main business involves the research, production, and sales of biomedical soft tissue repair materials, with revenue composition as follows: 57.27% from solution injection products, 37.97% from gel injection products, 3.01% from others, 1.50% from freeze-dried powder injection products, and 0.26% from facial implant threads [1] Group 2: Shareholder Insights - Huatai-PB Fund's Huatai-PB CSI 300 ETF (510300) is among Aimeike's top ten circulating shareholders, having reduced its holdings by 85,400 shares to 2.6773 million shares, representing 1.28% of circulating shares [2] - The ETF has generated a floating profit of approximately 20.2138 million CNY today and 22.9982 million CNY during the three-day increase [2] - The Huatai-PB CSI 300 ETF was established on May 4, 2012, with a current scale of 422.258 billion CNY, yielding 1.56% this year and 26.25% over the past year [2] Group 3: Fund Performance - The Huatai-PB Health ETF (516790) has also heavily invested in Aimeike, having reduced its holdings by 5,700 shares to 18,900 shares, accounting for 2.73% of the fund's net value [3] - The ETF has achieved a floating profit of approximately 142,500 CNY today and 162,200 CNY during the three-day increase [3] - The Huatai-PB Health ETF was established on August 12, 2021, with a current scale of 98.1452 million CNY, yielding 6.43% this year and 12.82% over the past year [3]